The conglomerate has nevertheless maintained its earnings forecast
Cybersecurity firm targets platforms that offer GLP-1 drugs such as Ozempic and Mounjaro
The reconstituted exco will continue to be led by Peter Wharton-Hood as the CEO.
The pharmaceutical group has received the necessary regulatory approvals from Chinese authorities to conclude two linked transactions
The company is in the process of delisting and shareholders have been offered 80c per share
Council for Medical Schemes claims board was unlawfully elected
SA’s high TB burden and strong clinical trial infrastructure allows it to play a key role in the trial, which aims to enrol 20,000 volunteers
Icon has clinical protocols, formularies and funding models used by more than half the medical scheme market
Drugmaker is also considering partnership with a retail pharmacy to offer a collect option for customers
The ENSafrica investigation included interviews with hospital staff and a review of more than 120,000 emails and documents
The company is racing to increase output of the weight-loss drug Wegovy amid shortages
Drugmaker expects to finalise deals within the next six months to help use idle capacity
Payout is part of the proceeds of the sale of group’s interest in Alliance Medical Group
Grillenberger bought shares when Advanced Health was trading under a cautionary and without the required clearance
Pharmaceutical and biotechnology company outlines plans for experimental respiratory syncytial virus vaccine to offset decline in sales of its Covid vaccine
Novo Nordisk’s patents for Wegovy expire in China in 2026, in Japan and Europe in 2031 and in the US in 2032
HEPS rose 1%, benefiting from a buyback of 1.7-million shares due to a tough environment
Peter Wharton-Hood says shareholders preferred to get dividends rather than wait for long-term rewards
Alvotech settles with J&J to launch Stelara biosimilar in Europe and Canada
